Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Philips has received FDA 510(k) clearance for new remote scanning and protocol management features on its Radiology Operations Command Center (ROCC). This vendor-agnostic solution enables expert radiologists to remotely assist technologists by controlling scans and adjusting protocols in real-time.
The multi-vendor platform, already widely used in North America and Europe, works with any MR or CT configuration. A pilot study at Imperial College Healthcare NHS Trust demonstrated a 9% increase in scanning throughput and zero exam recall rates. The system facilitates remote collaboration while maintaining privacy and security standards, addressing the growing challenge of technologist shortages, particularly for complex procedures like cardiac MR.
Philips has unveiled its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024, featuring a 70 cm wide-bore design and integrated AI-enabled MR Smart Workflow solutions. The system is helium-free, making it the lightest 1.5T 70cm MRI system available, up to 1700kg lighter than conventional systems. The scanner integrates Smart Reading technology, a cloud-based AI toolset partnering with icometrix and Quibim for neurological and prostate cancer diagnostics. Key features include SmartSpeed technology offering up to 65% higher resolution or 3x faster scanning, and AI-enabled workflow solutions for enhanced efficiency. The system requires only 7 liters of helium that never needs refilling and saves nearly 40mWh in energy annually.
Philips (NYSE: PHG) announces the next phase of its holiday ad campaign featuring actor Adam Scott for its Philips Norelco grooming brand. The new creative spot showcases Scott as the holiday season's No. 1 Facial Hair Ambassador, paying tribute to Santa Claus while promoting the Philips Norelco Shaver S9000 Prestige. The campaign continues the partnership launched in April, focusing on personal growth and self-expression through facial hair grooming. Scott's product picks will be available at select retailers during the holiday season, including the Philips Norelco OneBlade 360.
Philips has received FDA 510(k) clearance for its Spectral CT 7500 RT, the world's first spectral 4DCT respiratory-gated imaging system for radiation therapy. This innovative technology combines conventional and spectral CT capabilities in a single scan, enabling more precise radiation therapy planning by better visualizing tumor characteristics. The system reduces proton stopping-power ratio error by over 50% compared to conventional CT and creates stopping power ratio maps with less than 1% deviation, significantly improving treatment accuracy while sparing healthy tissue. This advancement allows for more personalized cancer treatment without adding extra steps to existing radiotherapy workflows.
Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, testing an innovative combined laser atherectomy and intravascular lithotripsy catheter. The device integrates two PAD treatments into a single solution, performed at the Cardiovascular Institute of the South in Louisiana on a 78-year-old male. The trial will enroll up to 155 patients at up to 30 U.S. sites to evaluate safety and efficacy in treating complex, calcified lesions. The study's primary endpoints include freedom from major adverse events within 30 days and achieving ≤50% residual stenosis post-procedure, with 12-month patient follow-up.
Philips (NYSE: PHG) has announced a partnership with Aspen Dental, bringing Philips Sonicare products to Aspen's network of over 1,100 dental offices. The collaboration will offer patients access to Philips Sonicare ExpertClean toothbrushes, Cordless Power Flossers, and Teeth Whitening Kits. The partnership includes the introduction of Philips' new Path to Health Toolset, developed with behavioral scientists and dental professionals to enhance patient care and education. This initiative aims to expand access to comprehensive oral care and support dental professionals in providing better patient outcomes both in-office and at home.
Philips has secured a $25 million contract with the U.S. Department of Defense to expand its RATE (Rapid Analysis of Threat Exposure) algorithm over the next four years. The AI-powered technology uses biomarkers from wearables for early infection detection in military personnel. RATE's effectiveness was demonstrated in studies, including a 2022 research showing COVID-19 detection 2.3 days before symptoms appeared in 9,381 DoD personnel. The algorithm, initially developed in 2019, analyzed 163 biomarkers from 36,000 hospital-acquired infection cases to develop risk scores for various infections.
Philips (PHG) reported Q3 2024 results with flat comparable sales at EUR 4.4 billion, primarily due to deteriorated demand in China while showing growth in other regions. The company achieved significant margin improvement with Adjusted EBITA margin increasing to 11.8% from 10.2%. Free cash flow was EUR 22 million, and comparable order intake decreased by 2% due to China decline. The company revised its full-year 2024 outlook, projecting comparable sales growth of 0.5-1.5%, with Adjusted EBITA margin around 11.5% and free cash flow around EUR 0.9 billion. Productivity initiatives delivered EUR 188 million in savings during Q3.
Philips (NYSE: PHG) and Medtronic Neurovascular announced a strategic advocacy partnership to improve stroke care access globally. Both companies joined the newly established World Stroke Organization (WSO) Advocacy Coalition, focusing on three key areas: raising public awareness of stroke symptoms, improving treatment access, and leveraging technology for integrated care systems.
The partnership addresses a critical health issue affecting 12 million people annually, with direct and indirect costs estimated at USD 900 billion, expected to double in 25 years. The collaboration aims to develop a global network of comprehensive stroke care centers and will be highlighted at the upcoming World Stroke Congress in Abu Dhabi.
Philips is showcasing its latest cardiology innovations at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting from October 27-30 in Washington D.C. The company's portfolio integrates artificial intelligence into imaging systems and software, along with specialized diagnostic and therapeutic devices to support complex procedures.
Key advancements include:
- AI-enabled cardiovascular ultrasound platform for structural heart disease diagnosis
- Intravascular ultrasound (IVUS) for improved patient outcomes in coronary interventions
- Instantaneous free-ratio (iFR) for physiologic measurement during PCI
- 3D Intracardiac Echocardiography (ICE) catheter for structural heart disease procedures
- EchoNavigator 4.0 for advanced 3D heart modeling and live fusion imaging
- Laser System for coronary and peripheral atherectomy and lead extraction
- IntraSight platform for streamlined interventional procedures
Philips will also host educational sessions and hands-on trainings at their Engagement Hub during the event.